ESMO 2022 | Optimizing treatment options for patients with muscle-invasive urothelial carcinoma

Andrea Necchi, MD, Istituto Nazionale dei Tumori, Milan, Italy, discusses the future treatment landscape of perioperative muscle-invasive urothelial carcinoma. The emergence of different biomarkers such as gene markers and tumor mutational burden (TMB) will enable more reliable selection of patients who will benefit from treatment more. Despite this, there is conflicting data of biomarkers and further research is necessary to optimize the use of biomarkers in the clinic. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.